Fredag 5 December | 12:53:59 Europe / Stockholm

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-12-05 11:09:00

Saudi Arabia has emerged as one of the world's most capital-strong markets for biotech investments. Swedish Alzinova is now positioning itself to capitalize on this opportunity through a Letter of Intent with a leading local healthcare provider. The objective is to secure both clinical infrastructure and financing for the upcoming Phase II study of the vaccine candidate ALZ-101.

Read the full interview at biostock.se:

Alzinova signs letter of intent with player in Saudi Arabia
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/